HZRM Haemophilie-Zentrum Rhein Main GmbH — Clinical Trial Site

11 Registered trials

4 Currently recruiting

Organisation

HZRM Haemophilie-Zentrum Rhein Main GmbH

Location

Frankfurt Am Main, Germany

Identifier

ORG-100047532

Address

Stresemannallee 15, Sachsenhausen, 60596, Germany

Departments

Diagnostik, Therapie und Erforschung von Gerinnungsstörungen, Immundefekten und HAE
Director of Haemophilia Centre Rhein Main – HZRM, Frankfurt
Haemophilia Centre
Haemophilie Zentrum Rhein Main
Hamophilie Zentrum Rhein Main
N/A
NA

Clinical trials at this site (11)

Search interface

An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Hereditary angioedema 10 2022-10-10
Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting

2024-517812-31-00 Haemophilia A 6 2025-05-21
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Hereditary Angioedema 5 2025-03-28
An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibito… Recruiting

2024-516741-39-00 Haemophilia A 6 2020-01-14
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Ended

2024-517757-27-00 Hereditary Angioedema (HAE) 6 2026-01-29
CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult… Ended

2024-516247-62-00 Hereditary Angioedema 5 2025-03-10
A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended

2022-502215-10-00 Haemophilia A (with or without inhibitors) 5 2023-05-04
A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu… Ended

2023-507268-37-00 Hereditary Angioedema 5 2024-07-29
CSL312_3003 Safety and Pharmacokinetic study in Subjects 2 to 11 Years of Age with Hereditary Angioedema Ended

2022-502386-13-00 Hereditary angioedema (HAE) 5 2024-05-10
A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended

2023-505904-41-00 Hereditary Angioedema Type I or II 5 2022-11-17
Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended

2024-510777-18-00 Hereditary angioedema 5 2021-06-15